glp-1 other benefits MCT2D GLP‑1 medications do more than

doi:10.1900/RDS.2014.11.202 Gorgojo-Martnez JJ, Mezquita-Raya P, Carretero-Gmez J, et al

0.4 kg with placebo) in people with T2D, without delay in gastric emptying or nausea and vomiting [37]

doi: 10.1007/s13668-025-00649-w

Among the several obesity therapies, phentermine, semaglutide, and tirzepatide exhibited the greatest prescription rates, with approximately 0.74 million, 0.42 million, and 0.25 million monthly prescriptions, respectively, as of February 2024

Additional possible effects encompass indigestion, bloating, burping, gas, reflux, heartburn, fatigue, dizziness, low blood pressure, reduced appetite, hair loss, rapid pulse, and injection site reactions

Oxyntomodulin and other dual GLP-1/glucagon receptors agonists reduce food intake and improve blood glucose levels, which makes them promising treatments for obesity, including in the course of PCOS [141]